NCT05681845View on ClinicalTrials.gov

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

PHASE1CompletedINTERVENTIONAL

Enrollment

205

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions

Haemophilia A

Interventions

DRUG

NNC0365-3769 (Mim8)

Participants will receive a single dose of Mim8 subcutaneously in the abdomen.

Trial Locations (1)

10117

Charité - Campus Charité Mitte - Charité Research Organisation GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY